title: Managing the risks of IBD therapy.
abstract: Successful management of the patient with inflammatory bowel disease (IBD) involves not only the induction and maintenance of remission, but also the optimization of the benefit-to-risk equation to achieve the greatest gain in quality of life. These risks range from intolerance to prescribed medications to potentially life-threatening sequelae (eg, sepsis) of immune suppression. A proper awareness of risk on the part of the physician and education of the patient can lead to early detection and institution of an appropriate management plan, including risk management and, optimally, primary prevention (eg, prophylactic vaccination). One should take the opportunity regularly to reassess the utility and efficacy of existing therapy, with the provision of ineffective therapies mandating urgent review. Overall, optimal management of the patient with IBD requires open dialogue between clinician and patient so that both are cognizant of the goals, benefits, and potential risks of therapy.
authors.affiliation: University of Calgary, TRW Building, Room 6D18, Calgary, Canada. cseow@ucalgary.ca
authors.forename: Cynthia H
authors.initials: CH
authors.lastname: Seow
authors.forename: Shanika
authors.initials: S
authors.lastname: de Silva
authors.forename: Gilaad G
authors.initials: GG
authors.lastname: Kaplan
authors.forename: Shane M
authors.initials: SM
authors.lastname: Devlin
authors.forename: Subrata
authors.initials: S
authors.lastname: Ghosh
authors.forename: Remo
authors.initials: R
authors.lastname: Panaccione
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D019804:Mesalamine / Q000009:adverse effects / Q000627:therapeutic use; D012308:Risk Management; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D012460:Sulfasalazine; D019804:Mesalamine